Perrigo (PRGO)
(Delayed Data from NYSE)
$27.69 USD
-0.49 (-1.74%)
Updated Sep 6, 2024 04:00 PM ET
After-Market: $27.72 +0.03 (0.11%) 7:58 PM ET
3-Hold of 5 3
A Value D Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$27.69 USD
-0.49 (-1.74%)
Updated Sep 6, 2024 04:00 PM ET
After-Market: $27.72 +0.03 (0.11%) 7:58 PM ET
3-Hold of 5 3
A Value D Growth C Momentum B VGM
Zacks News
Zacks.com featured highlights: Boot Barn, Perrigo, Boise Cascade, DXC Technology and Koppers
by Zacks Equity Research
Zacks.com featured highlights: Boot Barn, Perrigo, Boise Cascade, DXC Technology and Koppers
Bet on These 5 GARP Stocks Based on Low PEG Ratio
by Zacks Equity Research
A lower PEG ratio, preferably less than 1, is always better for GARP investors.
Company News For Nov 10, 2017
by Zacks Equity Research
Companies in the News are: ROKU,M,SEDG,PRGO
Perrigo (PRGO) Q3 Earnings Top, 2017 View Raised, Shares Up
by Zacks Equity Research
Perrigo (PRGO) posts better-than-expected earnings with revenues also beating estimates. The company ups its guidance, courtesy of a continued positive execution across all business segments.
Is a Beat in the Cards for Perrigo (PRGO) in Q3 Earnings?
by Zacks Equity Research
Perrigo's (PRGO) product acquisitions and new product launches in the Rx segment might boost sales in the coming quarters.
4 Medical Product Stocks Likely to Top Q3 Earnings Estimates
by Zacks Equity Research
The MedTech space received a sudden jolt when White House pulled the plug on Obamacare subsidies.
Perrigo's Stock Up, Starboard's CEO Calls it a Key Pick
by Zacks Equity Research
Perrigo's (PRGO) shares rise with Jeff Smith, CEO of Starboard Value, certifying the company as a top investment pick, courtesy its highly potential generic business.
Perrigo's (PRGO) OTC Version of Nexium Secures FDA Approval
by Zacks Equity Research
Perrigo (PRGO) gains an FDA consent for the OTC version of AstraZeneca's Nexium post the ongoing patent lawsuit settlement through an agreement.
The Zacks Analyst Blog Highlights: Mylan, Perrigo, Esperion's, Zynerba and Valeant
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Mylan, Perrigo, Esperion's, Zynerba and Valeant
Company News For August 11, 2017
by Zacks Equity Research
Companies in the new are: PRGO,KSS,EAT,LYV
Pharma Stock Roundup: Mylan Misses, Perrigo Tops in Q2, Zynerba Plunges on Study Failure
by Arpita Dutt
This week, focus was on earnings announcements from companies like Mylan (MYL), Perrigo and Endo.
Perrigo (PRGO) Q2 Earnings & Sales Top, 2017 View Raised
by Zacks Equity Research
Perrigo (PRGO) posts better-than-expected results with revenue beating estimates. The company also ups its earnings outlook, courtesy a continued positive execution across all business segments.
Perrigo Company (PRGO) Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Perrigo's (PRGO) Rx segment is likely to continue hurting the company's performance. However, product acquisitions and new product launches in the same might boost sales in the coming quarters.
Generic Drug Stocks Take a Hit: Here's Why
by Arpita Dutt
As generic drug pricing concerns loom large, Teva (TEVA) and other players in the generic market saw their shares tumble last week.
Perrigo Company Gets FDA Approval for Generic Topical Gel
by Zacks Equity Research
Perrigo Company plc (PRGO) receives approval from the FDA for generic version of Androgel Topical Gel, for replacement therapy in males.
Why Is Perrigo (PRGO) Up 5% Since the Last Earnings Report?
by Zacks Equity Research
Perrigo (PRGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Company News for June 01, 2017
by Zacks Equity Research
Companies in the News are: KORS,ADI,PRGO,JILL
Perrigo's (PRGO) Q1 Earnings Beat Estimates, Guidance Intact
by Zacks Equity Research
Perrigo Company plc (PRGO) reported first-quarter 2017 earnings of $1.05 per share which beat the Zacks Consensus Estimate of 98 cents per share by 7.1%.
Perrigo Company (PRGO) Q1 Earnings: Disappointment in Store?
by Zacks Equity Research
Perrigo Company plc (PRGO) is expected to report first-quarter 2017 results later this month.
Generic Drugmakers Tumble as Perrigo Discloses DoJ Search
by Arpita Dutt
With Perrigo (PRGO) disclosing that DoJ search warrants were executed at its corporate offices, industry-wide pricing practices are back in focus.
Perrigo Launches First to Market OTC Equivalent of Rogaine
by Zacks Equity Research
Perrigo Company plc (PRGO) announced the first-to-market launch of the over-the-counter ("OTC") version of hair re growth drug for the brand equivalent of women's Rogaine 5% minoxidil foam (minoxidil topical aerosol, 5% foam).
Perrigo to Sell Tysabri Royalties; Issues Tepid 2017 View
by Zacks Equity Research
The company also announced that it has signed an agreement to divest the royalties it receives in multiple sclerosis drug, Tysabri, in order to monetize the asset.
Perrigo Company (PRGO) Q4 Earnings: Disappointment in Store?
by Zacks Equity Research
Perrigo Company plc (PRGO) is expected to report fourth-quarter 2016 results this month. Perrigo has a mixed track record as the company beat expectations in two of the last four quarters and missed the same in the other two.
Perrigo's (PRGO) Generic Version of Topicort Okayed by FDA
by Zacks Equity Research
Perrigo Company plc (PRGO) recently announced that the FDA has approved its first-to-file AB rated generic version of Taro Pharmaceuticals's Topicort spray, 0.25% indicated for the treatment of plaque psoriasis in patients of 18 years or above.
Is Perrigo Company (PRGO) a Great Stock for Value Investors?
by Zacks Equity Research
Let's delve into the value metrics of Perrigo Company (PRGO) and determine whether it is a good value investment right now.